RUA Life Sciences PLC Full Year Results Investor Presentation
13 Julio 2021 - 1:00AM
RNS Non-Regulatory
TIDMRUA
RUA Life Sciences PLC
13 July 2021
RNS REACH
13 July 2021
RUA Life Sciences plc
("RUA" or the "Company")
Full Year Results Investor Presentation
Results Webinar: open to all investors
RUA Life Sciences (AIM:RUA), the holding company of a group of
medical device businesses focused on the exploitation of the
world's leading long-term implantable biostable polymer
(Elast-Eon(TM) ), will be conducting an Investor Presentation
webinar covering their FY results for the year ended 31 March
2021.
The event will take place at 2.00pm on Friday 16th July
2021.
The online presentation is open to all existing and potential
shareholders. Questions can be submitted during the presentation to
be addressed at the end.
To register for the event, please go to:
https://www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-full-year-results-investor-presentation-16th-july-2021
A recording will be available after the event at
https://www.equitydevelopment.co.uk/research/tag/rua-life-sciences
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 9999 6400
Equity Development Tel: +44 (0) 20 7065 2692
Hannah Crowe
Shore Capital (Nominated Adviser and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0) 20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM), a
long-term implantable polyurethane.
Whether it is licensing Elast-Eon(TM), manufacturing a device or
component or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and over 14 years of successful clinical use,
RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical End-to-end contract designer and manufacturer
: of medical devices and implantable fabric
specialist.
RUA Biomaterials: Licensor of Elast-Eon(TM) polymers to the
medical device industry.
RUA Vascular: Commercialisation of large bore polymer sealed
grafts and soft tissue patches.
RUA Structural Development of polymeric leaflet systems
Heart: for heart valves.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDRIGBDGBD
(END) Dow Jones Newswires
July 13, 2021 02:00 ET (06:00 GMT)
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De May 2023 a May 2024